Vimta Labs Ltd

- There is no specific mention of any current or planned fundraising through debt or equity in the provided document. - The company maintains a net debt-free balance sheet with cash and cash equivalents of INR 545 million, indicating a strong cash position. - Capex plans for FY '26 and '27 around INR 25 crores annually are funded internally, primarily for biologics and capacity expansion across verticals. - Expansion and growth plans appear to be backed by internal accruals and existing resources rather than external fundraising. - The management did not indicate any immediate need for raising external funds during the call.

- Vimta Labs has planned a total capex of around INR100 crores for the current financial year, on track as per plan. - Biologics segment capex is around INR25 crores for this year, with a similar amount planned for the next year ('27). - Capex is spread across pharmaceuticals, food, and electrical & electronic testing verticals. - Investments focus on expanding capacities, including new equipment and infrastructure. - Some capex backed by visibility from client pipelines; others are inherent to newly created capacities. - Clinical research requires minimal capex as studies in patient populations are off-site. - The biologics segment expansion includes backward integration from preclinical to formulation development. - Phase 1 of the new facility is largely utilized, with Phase 2 currently about 50-60% utilized and expected to support future growth.

- Vimta Labs expects continued growth primarily in pharmaceutical research and testing services and food testing, which form the major revenue contributors. - All verticals—pharma, food, electronics—are anticipated to grow at similar rates (7.5% to 9%), with pharma dominating revenue share (~65%) and food contributing ~20%. - Biologics and large molecule formulation development services are emerging growth areas, with commercialization expected by Q1 FY 2027. - Expansion in capacity across all verticals (pharma, food, electronics, preclinical, GMP testing) has been done to support growth without immediate capacity constraints. - Increasing client demand for biologics development and outsourcing trends will further boost pharma segment growth. - International markets offer opportunities for new business and market share gain, particularly in pharma. - Electronics and environment testing show stable to moderate growth but contribute smaller revenue shares. - Overall, the company targets maintaining and improving the INR100 crore quarterly revenue run-rate, supported by ongoing capex and expanding client base.

- Vimta Labs has reported strong growth with Q2 FY '26 revenue crossing INR 100 crores, up 22.3% YoY. - PAT for H1 FY '26 grew 25.5% YoY at INR 388 million with PAT margin at 19%. - Management expects continued growth primarily from pharmaceutical research/testing and food testing services. - New biologics formulation development services to commercialize by Q1 FY '27, expected to contribute to growth. - No immediate capacity constraints due to recent infrastructure expansions; incremental revenues expected as resources and equipment scale up. - Margins are stable across verticals, with environment testing margins slightly lower. - Capex of ~INR 25 crores planned for biologics over 2 years to support lifecycle integration and new service lines. - Overall, the company anticipates sustained earnings growth driven by expanding capacities and new service offerings in biopharma.

- The company did not provide explicit current orderbook or pending order values during the call. - They mentioned having strong order pipelines, especially in the pharmaceutical segment, mainly supporting generic product development. - Preclinical business supports both discovery (35%) and generic, specialty chemicals, regulatory work (65%). - The clinical trial business pipeline is growing, with intensified business development operations. - The newly added CMO/CRADS vertical is part of the expansion backed by visibility of pipelines and client interest. - Expansion into biologics and formulation development is driven by growing demand and client requests. - The company bases some capex on visible pipelines, indicating confidence in upcoming orders. - Defence segment has continuous work with expanding clientele, implying ongoing order flow.